CN106819750A - 一种辅助降血压降血糖的固体饮料及其制备方法 - Google Patents
一种辅助降血压降血糖的固体饮料及其制备方法 Download PDFInfo
- Publication number
- CN106819750A CN106819750A CN201710016859.5A CN201710016859A CN106819750A CN 106819750 A CN106819750 A CN 106819750A CN 201710016859 A CN201710016859 A CN 201710016859A CN 106819750 A CN106819750 A CN 106819750A
- Authority
- CN
- China
- Prior art keywords
- powder
- flavouring
- auxiliary material
- solid beverage
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 65
- 239000008280 blood Substances 0.000 title claims abstract description 65
- 235000013361 beverage Nutrition 0.000 title claims abstract description 22
- 239000007787 solid Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 92
- 239000000463 material Substances 0.000 claims abstract description 43
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 16
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 16
- 235000010408 potassium alginate Nutrition 0.000 claims abstract description 16
- 244000179886 Moringa oleifera Species 0.000 claims abstract description 15
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 15
- 229920001353 Dextrin Polymers 0.000 claims abstract description 14
- 239000004375 Dextrin Substances 0.000 claims abstract description 14
- 235000019425 dextrin Nutrition 0.000 claims abstract description 14
- 239000000737 potassium alginate Substances 0.000 claims abstract description 14
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims abstract description 14
- 240000005979 Hordeum vulgare Species 0.000 claims abstract description 13
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 13
- 229920001202 Inulin Polymers 0.000 claims abstract description 13
- 229930003944 flavone Natural products 0.000 claims abstract description 13
- 235000011949 flavones Nutrition 0.000 claims abstract description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 13
- 229940029339 inulin Drugs 0.000 claims abstract description 13
- 235000013336 milk Nutrition 0.000 claims abstract description 13
- 239000008267 milk Substances 0.000 claims abstract description 13
- 210000004080 milk Anatomy 0.000 claims abstract description 13
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 12
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims abstract description 12
- 150000002213 flavones Chemical class 0.000 claims abstract description 11
- 241000195493 Cryptophyta Species 0.000 claims abstract description 10
- 235000021307 Triticum Nutrition 0.000 claims abstract description 9
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 7
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 7
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 6
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 6
- 240000007594 Oryza sativa Species 0.000 claims abstract description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 6
- 235000009566 rice Nutrition 0.000 claims abstract description 6
- 235000013557 nattō Nutrition 0.000 claims abstract description 5
- 244000269722 Thea sinensis Species 0.000 claims abstract 3
- 244000098338 Triticum aestivum Species 0.000 claims abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 229920001503 Glucan Polymers 0.000 claims description 8
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000000811 xylitol Substances 0.000 claims description 6
- 235000010447 xylitol Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 229960002675 xylitol Drugs 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- 239000004383 Steviol glycoside Substances 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims description 5
- 235000019411 steviol glycoside Nutrition 0.000 claims description 5
- 229930182488 steviol glycoside Natural products 0.000 claims description 5
- 150000008144 steviol glycosides Chemical class 0.000 claims description 5
- 235000019202 steviosides Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 235000013311 vegetables Nutrition 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 2
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 2
- 244000082204 Phyllostachys viridis Species 0.000 claims description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 2
- 239000011425 bamboo Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 230000003345 hyperglycaemic effect Effects 0.000 claims 3
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 17
- 239000002253 acid Substances 0.000 abstract description 17
- 239000011591 potassium Substances 0.000 abstract description 17
- 229910052700 potassium Inorganic materials 0.000 abstract description 17
- 241001474374 Blennius Species 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 12
- 230000007774 longterm Effects 0.000 abstract description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract description 2
- 229920002498 Beta-glucan Polymers 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 235000008935 nutritious Nutrition 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 32
- 230000036772 blood pressure Effects 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 241001122767 Theaceae Species 0.000 description 10
- 230000002265 prevention Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 241000209140 Triticum Species 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 229940026314 red yeast rice Drugs 0.000 description 4
- 235000019710 soybean protein Nutrition 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- CAXNYFPECZCGFK-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylacetonitrile Chemical compound C=1C=CC=NC=1C(C#N)C1=CC=CC=C1 CAXNYFPECZCGFK-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000195627 Chlamydomonadales Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000195633 Dunaliella salina Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000544058 Halophila Species 0.000 description 1
- 240000008892 Helianthus tuberosus Species 0.000 description 1
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 240000006859 Jasminum officinale Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920000377 Sinistrin Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940003871 calcium ion Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/10—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
- A23C11/103—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
- A23F5/36—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee
- A23F5/40—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee using organic additives, e.g. milk, sugar
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种辅助降血压降血糖的固体饮料及其制备方法,主要的功效成分为下述原料中的1种或1种以上:海藻酸钾(低分子量海藻酸钾)、山楂提取物、小麦低聚肽、辣木叶粉或辣木叶提取物、红曲米粉、纳豆粉、燕麦β‑葡聚糖、壳寡糖、盐藻及提取物、竹叶黄酮、葛根或葛根提取物;辅料为下述原料中的1种或1种以上:菊粉、抗性糊精、豆粉、茶粉、奶粉、大麦若叶粉柑橘纤维粉、咖啡粉。制备方法,包括以下步骤:步骤1:粉碎过筛;步骤2:称量;步骤3:混合搅拌。本发明安全性好,无任何副作用,避免了长期服用西药导致的并发症和副作用;食用方便,易于携带,营养丰富,口味好;辅助降血压、降血脂作用机理明确,经济实用,适用范围广。
Description
技术领域
本发明涉及固体饮料领域,尤其涉及一种采用海藻酸钾为原料的辅助降血压、降血脂固体饮料及其制备方法。
背景技术
高血压是指以体循环动脉血压(收缩压和/或舒张压)增高为主要特征(收缩压≥140毫米汞柱,舒张压≥90毫米汞柱),可伴有心、脑、肾等器官的功能或器质性损害的临床综合征。《中国居民营养与慢性病状况报告(2015)》显示,2012年我国18岁及以上成人高血压患病率为25.2%,也就是说,每4个成年人当中就有一个高血压患者。高血压是心脏病、脑卒中、肾脏病和糖尿病发病和死亡的最大的危险因素,心脑血管病死亡占总死亡的41%,而且发病率日益增高和有年轻化的趋势。
高脂血症是指血脂水平过高,可直接引起一些严重危害人体健康的疾病,如动脉粥样硬化、冠心病、胰腺炎等。高血脂引起的动脉粥样硬化能导致外周血管的阻力增加,心脏射血阻力增大,加重心脏的负担,血压升高。当血脂增高时血粘度就增高,使血流阻力增加,从而血压就升高。现代医学证明,高血压患者大部分伴随着高血脂,对于血压血脂同时高于正常水平,其治疗方式首要的降低血脂,降低外周血管的阻力。
高血压和高血脂的病因除了与家族遗传、生活环境有关外、生活饮食习惯-如食盐摄入过多,高脂肪和高蛋白饮食等因素有关。目前控制血压和血脂的方法除了药物,另外就是控制饮食,改变生活习惯,尤其是膳食疗法在高血压和高血脂的预防和控制方面起到了不可代替的作用。
目前治疗高血压的西药主要有6大类,即β受体阻滞剂、利尿剂、钙离子拮抗剂、血管紧张素Ⅱ受体拮抗剂、血管紧张肽转化酶抑制剂、α-受体阻滞剂。降血脂的西药主要有胆酸整合剂、HMG—CoA还原酶、抑制剂烟酸及其衍生物、贝特类、普罗布考、泛硫乙胺、弹性酶、Omega—3脂肪酸等。降血压和降血脂的药物在治疗高血压和高血脂的同时,也给机体带来损伤,副作用和不良反应多。另外,目前治疗降血压和降血脂的西药都是单一功能,没有既降低血压又能降低血脂。传统的中医药有这样的复方在控制血压的同时也降低血脂,但是有些中药有一定的毒副作用,长期服用对身体的损害比较大,因此研发安全无毒、可以长期使用,服用方便的降血压、降血脂的产品是目前国内外致力于高血压和高血脂预防和治疗的重要课题。
发明内容
本发明的目的是克服现有降血压降血糖药物存在的上述的问题,提供一种辅助降血压、降血脂的固体饮料及其制备方法。
本发明为实现上述目的所采用的技术方案是:
一种辅助降血压降血糖的固体饮料,按照重量百分含量包括以下组分:海藻酸钾0.1-95%、山楂提取物0-95%、小麦低聚肽0-95%、辣木叶粉或辣木叶提取物0-95%、红曲米粉0-90%、纳豆粉0-90%、燕麦β-葡聚糖0-90%、壳寡糖0-50%、盐藻及提取物0-90%、竹叶黄酮0-90%、葛根或葛根提取物0-85%;菊粉0-90%、抗性糊精0-90%、豆粉0-95%、茶粉0-95%、奶粉0-95%、大麦若叶粉0-85%、柑橘纤维粉0-90%、咖啡粉0-95%;其中,辅料为菊粉、抗性糊精、豆粉、茶粉、奶粉、大麦若叶粉、柑橘纤维粉、咖啡粉,其余为功效成分;且辅料重量百分含量不同时为0。
优选地,主要的功效成分按照重量百分含量包括:海藻酸钾(低分子量海藻酸钾)0.1-95%、山楂提取物0.1-95%、小麦低聚肽0.1-95%、辣木叶粉或辣木叶提取物0.1-95%、红曲米粉0.1-90%、纳豆粉0.1-90%、燕麦β-葡聚糖0.1-90%、壳寡糖0.1-50%、盐藻及提取物0.1-90%、竹叶黄酮0.1-90%、葛根或葛根提取物0.1-85%。
优选地,辅料按照重量百分含量包括:菊粉0.1-90%、抗性糊精0.1-90%、豆粉0.1-95%、茶粉0.1-95%、奶粉0.1-95%、大麦若叶粉0.1-85%、柑橘纤维粉0.1-90%、咖啡粉0.1-95%。
还包括矫味剂,矫味剂用量为功效成分和辅料总量的0.01~90%;矫味剂选自甜菊糖苷、木糖醇、低聚果糖、异麦芽糖醇、海藻糖、抹茶粉、果蔬粉、食用香精、柠檬酸、柠檬酸钠中的一种或几种。
优选地,矫味剂按照重量百分含量包括:甜菊糖苷0.1-50%、木糖醇0.1-50%、低聚果糖0.1-50%、异麦芽糖醇0.1-50%、海藻糖0.1-50%、抹茶粉0.1-90%、果蔬粉0.1-80%、食用香精0.01-70%、柠檬酸0.01-70%、柠檬酸钠0.01-70%。
上述辅助降血压降血糖的固体饮料的制备方法,包括以下步骤:
步骤1:粉碎过筛,将功效成分、辅料和矫味剂粉碎过筛,保证要进行加工的固体饮料的原料、辅料和矫味剂的粒度一致;
步骤2:称量,将功效成分、辅料和矫味剂进行精确称量,备用;
步骤3:混合搅拌,将称量好的功效成分、辅料、矫味剂按照配方进行混合搅拌混合均匀。
包括以下步骤4:制粒,将混合好的原料,根据需要进行制粒,粒度为20-60目。
所述步骤1中,功效成分、辅料和矫味剂粉碎过筛,100%过80目。
所述步骤3中,采用等量递增方法进行混合搅拌,保证功效成分、辅料、矫味剂混合均匀。
本发明的辅助降血压、降血脂的固体饮料,安全性好,无任何副作用,避免了长期服用西药导致的并发症和副作用;本发明制备的固体饮料食用方便,易于携带,营养丰富,口味好。另外本发明制备的固体饮料辅助降血压、降血脂作用机理明确,经济实用,适用范围广。
具体实施方式
海藻酸钾(低分子量海藻酸钾)是由海带提取的,是可溶性多糖、膳食纤维,在胃肠里具有吸水性、吸附性、阳离子交换和凝胶过滤等作用,吸附胆固醇和胆汁酸等有机物,抑制人体对其吸收, 降低血清和肝脏中的胆固醇,抑制总脂肪和总脂肪酸浓度上升。海藻酸钾(低分子量海藻酸钾)能够净化血液、养护血管。主要表现在通过调节血管平滑肌细胞浆内游离钙离子浓度的升高,抑制血管平滑肌细胞的增殖从而抑制血管壁的增厚。这对于各种心脑血管疾病的治疗和预防都有重大的意义,并能从根本上预防各种心脑血管疾病的产生。低分子量海藻酸钾,在ZL200780101830.1和US8,686,053B2专利中有记载)。
山楂提取物是蔷薇科植物山楂果实的提取物,山楂提取物中的黄酮可显著降低实验性高血脂动物的血清总胆固醇、低密度脂蛋白胆固醇和载脂蛋白B的浓度,显著升高高密度脂蛋白和载脂蛋白A浓度。山楂降血脂作用是通过抑制肝脏胆固醇的合成,促进肝脏对血浆胆固醇的摄人而发挥降血脂作用,山楂黄酮还可降低动脉粥样硬化发生的危险性。
辣木叶是原产于印度的多年生热带落叶乔木辣木树(又称为鼓槌树)的树叶,可食用。辣木叶片、果荚富含多种矿物质、维生素、20种氨基酸、46种抗氧素和36种自然防炎体和矿物质。辣木叶粉有降血糖、降脂、降压、抗肿瘤、抗氧化、通便、利尿、驱虫、改善睡眠等功效。
小麦低聚肽是小麦蛋白酶解产物,能抑制血管紧张素转化酶的活性,使血管紧张素原不能转变成能使血压升高的血管紧张素Ⅱ,从而生理地降低血压,而对正常血压不起用。
红曲粉是以籼米为原料,采用现代生物工程技术分离出优质的红曲霉菌,经液体深层发酵精制而成,是一种纯天然、安全性高、有益于人体健康的食品添加剂,而且本品色泽鲜艳、色调纯正、饱满、光热稳定性好,是天然绿色食品理想的着色剂。红曲粉是国际上唯一利用微生物大规模生产的食用天然色素。红曲性甘、温、无毒,主治消食活血,健脾燥胃,治赤白痢下水谷。代谢途径表明,人体自身合成胆固醇需经过一系列代谢过程,其中关键就是羟甲基戍二酰辅酶A(HMG-CoA)在其还原酶(HMG-CoA-R)的作用下生成甲羟戊酸,再进一步合成胆固醇。红曲中有效成份正是HMG-CoA还原酶的竞争性抑制剂,从而就阻断了合成胆固醇的通路,起到治疗与预防心脑血管疾病的作用。
燕麦β-葡聚糖,是存在于燕麦胚乳和糊粉层细胞壁的一种非淀粉多糖。它由单体β-D-吡喃葡萄糖,通过β-(1→3)和β-(1→4)糖苷键连接起来形成的一种高分子聚合物。燕麦食品具有降低血脂和血清胆固醇的作用,对预防和治疗心脑血管疾病以及糖尿病有重要功效,其中,起保健作用的有效成分是燕麦中的β-葡聚糖。
壳寡糖是由壳聚糖解聚制成,是甲壳素、壳聚糖产品的升级产品。现代医学研究证明:壳寡糖能安全温和的降低胆固醇。壳寡糖能阻止脂肪的吸收,并且促进人体血液内的胆固醇代谢。
盐藻及提取物盐藻, 也称杜氏盐藻,隶属于绿藻门绿藻纲团藻目盐藻科盐藻属,为绿色单细胞藻, 形体微小,无细胞壁,具有糖蛋白形成的包被。盐藻提取物对“实验性动脉粥样硬化预防作用的研究”及国内外500多篇临床报告中明确指出:盐藻提取物对调节血压、降低血脂、降血糖都有显著预防和辅助治疗作用。
竹叶黄酮是从竹叶中提取出来的具有生理活性的生物黄酮,包括黄酮类、内酯类和酚酸类化合物,是一组复杂的、而又具有相互协同增效作用的混合物,具有保护心脑血管,调节血脂,降低血液粘稠度的作用。
葛根为豆科植物野葛的干燥根,习称野葛,性甘、辛,凉。有解肌退热,透疹,生津止渴,升阳止泻之功。常用于表证发热,项背强痛,麻疹不透,热病口渴,阴虚消渴,热泻热痢,脾虚泄泻。现代医学研究证明,葛根提取物含有葛根黄酮,其具有扩张血管,改善血液循环;降低心肌耗氧量,抑制癌细胞;增加冠脉流量,调整血液微循环;治疗各年龄阶段的突发性耳聋;降低心脑血管疾病危险。
菊粉是一种天然多聚果糖,主要从菊科植物菊芋和菊苣中提取。菊粉在肠道末端前,自身就发酵成短链脂肪酸和乳酸盐,乳酸盐是肝脏代谢的调节剂。短链脂肪酸(醋酸盐和丙酸盐)在血液里可作燃料,丙酸盐抑制胆固醇的合成。摄入菊粉可有效降低血清总胆固醇和低密度脂蛋白胆固醇,提高高密度脂蛋白/低密度脂蛋白比率,改善血脂状况。
抗性糊精是一种低热量葡聚糖,属于低分子水溶性膳食纤维。研究发现,具有降低胆固醇的作用,主要是因为抗性糊精能降低胆固醇和胆盐的吸收,可用于预防中度高胆固醇血症。
豆粉含有豆固醇和钾、镁、钙能加强心机血管的兴奋,改善心机营养,降低胆固醇,促进血流防止血管痉挛。
茶粉是通过萃取手段提炼茶叶中的有效成分,含有大量的茶叶氨酸、茶多酚、茶多糖、γ-氨基丁酸等,茶粉中的有效成分能扩张血管,使血压下降,达到预防和调节血压的作用。
大豆蛋白粉是蛋白质含量为50-65%的粉状大豆蛋白产品,具有大豆蛋白质所具有各种营养和健康功效,经进一步加工可得到组织化大豆蛋白、大豆浓缩蛋白、功能性大豆浓缩蛋白和分离蛋白。试验证明:以高血脂症大鼠为模型,研究大豆蛋白的调节血脂作用,大豆蛋白能明显降低高血脂症大鼠血清胆固醇和甘油三酯,因而具有降低血脂功能。
大麦若叶粉是大麦苗粉,《本草纲目》中记载,“麦苗,辛寒无毒。煮汁滤服,除烦闷,退胸隔热,利小肠,作斋食,甚益颜色。”大麦若叶粉是“碱性食品之王”含有大量膳食纤维、维生素C、β—胡萝卜素和抗氧化酵素等营养成分。大麦苗粉中含有2-O-GIV 是属于类黄酮(Flavonoid)族,它可减少动脉中脂质的过氧化作用,减少发生动脉硬化症。实验室的研究发现,它可以与造成过氧化作用的金属离子螯合或结合,此外它还能清除动脉中的因脂肪氧化产生的有害自由基。
咖啡粉(三合一咖啡粉)含有咖啡因、丹宁酸、蛋白质、挥发性脂肪、矿物质等营养成分。咖啡中含有的有效成分可增加高密度胆固醇,加速代谢坏的胆固醇,减少冠状动脉粥样化、长饮咖啡能降低中风机率。
本发明采用药食同源的中药和证明过安全性的新资源食品作为原料。本发明以海藻酸钾(低分子量海藻酸钾)0.1-95%、山楂提取物0.1-95%、小麦低聚肽0.1-95%、辣木叶粉或辣木叶提取物0.1-95%、红曲米粉0.1-90%、纳豆粉0.1-90%、燕麦β-葡聚糖0.1-90%、壳寡糖0.1-50%、盐藻及提取物0.1-90%、竹叶黄酮0.1-90%、葛根或葛根提取物0.1-85%其中的2种或2种以上组方为主要的功效成分,以菊粉0.1-90%、抗性糊精0.1-90%、豆粉0.1-95%、茶粉0.1-95%、奶粉0.1-95%、大麦若叶粉0.1-85%、柑橘纤维粉0.1-90%、咖啡粉0.1-95%等中的一种或几种为辅料,添加或不添加甜菊糖苷0.1-50%、木糖醇0.1-50%、低聚果糖0.1-50%、异麦芽糖醇0.1-50%、海藻糖0.1-50%、抹茶粉0.1-90%、果蔬粉0.1-80%、食用香精0.01-70%、柠檬酸0.01-70%、柠檬酸钠0.01-70%等中的一种或几种为矫味剂。
选取了11种具有辅助降血压、降血脂功能的功效成分原料,选定其中的1种或1种以上作为辅助降血压、降血脂的主要功效成分的原料,这些原料是药食同源或是新资源食品,协同作用,互补互促,无任何配伍禁忌,既从根本上增强机体的功能,扩张血管,降低血压,降低血清总胆固醇、甘油三酯,预防动脉粥样硬化或阻止其进展,修复血管,增加血管弹性,从而达到辅助降血压、降血脂的目的。
添加辅料是增加营养成分,补充血压、血脂异常的人群的营养摄入,选取添加的辅料是在主要功效原料的辅助降血压、降血脂的功效的基础上,补充营养的同时,增加血压和血脂增高人群的膳食纤维摄入,膳食纤维能抑制胆固醇吸收,促进肠蠕动,促进肠道排空和排泄,从而促进胆固醇的代谢。
矫味剂是为了调整口味、香味,增加固体饮料的适口性,方便血压、血脂增高人群食用。
本发明辅助降血压、降血脂固体饮料的制备方法如下:
步骤1:粉碎过筛,将原料、辅料和矫味剂根据其粒度情况决定是否进行粉碎,如果原料、辅料和矫味剂的颗粒粒度一致,则不需要粉碎,如果原料、辅料和矫味剂的颗粒粒度不一致,则需要粉碎过筛,保证要进行加工的固体饮料的原料、辅料和矫味剂的粒度一致;
步骤2:称量,将原料、辅料和矫味剂进行精确称量,备用;
步骤3:混合搅拌,将称量好的原料、辅料、矫味剂按照配方进行混合搅拌,采用等量递增方法进行混合搅拌,保证原料、辅料、矫味剂混合均匀;
步骤4:制粒,将混合好的原料,根据需要进行制粒(如果配方组合在温水中溶解的好则不需要制粒),达到需要的粒度20-60目。
步骤5:分装、包装,将混合好的物料或是制好粒的物料按照包装要求进行分装、包装,检验合格后,入库。
实施例1:
选取1种主要功效成分海藻酸钾(低分子量海藻酸钾),添加辅料豆粉或茶粉或奶粉、抗性糊精或咖啡粉。海带与豆粉或奶粉或茶粉或咖啡粉,二者之间没有任何配伍禁忌,所以,组方不存在安全问题。
具体的配方组成为(按重量百分数):
茶粉配方:
海藻酸钾(低分子量海藻酸钾):30
茶粉:70
咖啡粉配方:
海藻酸钾(低分子量海藻酸钾):20
三合一咖啡粉:80
奶茶粉配方:
海藻酸钾(低分子量海藻酸钾):20
茶粉:50
奶粉:15
抗性糊精:15
豆粉配方:
海藻酸钾(低分子量海藻酸钾):20
豆粉:80
生产加工方法如下:
步骤1. 粉碎过筛:将上述原辅料粉碎过筛,100%过80目,备用;
步骤2. 称重配料:按配方比例称取原辅料;
步骤3. 混合搅拌:将配好后的粉料装入混合机内搅拌30min;
步骤4. 分装:将搅拌后的粉料用自动灌装机进行分装;
步骤5. 包装:将分装后的半成品包装入库;
实施例2:
选取3种主要功效成分原料海藻酸钾(低分子量海藻酸钾)、壳聚糖、竹叶黄酮,添加辅料菊粉、奶粉、抗性糊精,添加甜菊糖苷、低聚果糖为矫味剂。海带、壳聚糖、竹叶黄酮、菊粉是药食同源物质和新食品原料,奶粉和抗性糊精为普通食品,它们之间没有配伍禁忌,所以,组方不存在安全问题。
具体的配方组成为(按重量百分数):
海藻酸钾(低分子量海藻酸钾):30
壳聚糖:15
竹叶黄酮:10
菊粉:22
抗性糊精:20
低聚果糖:2.5
甜菊糖苷: 0.5
生产加工方法如下:
步骤1. 粉碎过筛:将上述原辅料粉碎过筛,100%过80目,备用;
步骤2. 称重配料:按配方比例称取原辅料。;
步骤3. 混合搅拌:将配好后的粉料装入混合机内搅拌30min;
步骤4. 制粒: 将混合好的物料进行制粒,过筛,需要的粒度20-60目;
步骤5. 分装:将搅拌后的粉料用自动灌装机进行分装;
步骤6. 包装:将分装后的半成品包装入库。
实施例3:
选取4种主要功效成分原料海藻酸钾(低分子量海藻酸钾)、红曲、燕麦β-葡聚糖、葛根提取物,添加辅料大麦若叶粉、茶粉,添加木糖醇、海藻糖为矫味剂。海带、燕麦β-葡聚糖、葛根都是药食同源物质和新食品原料,它们之间没有任何配伍禁忌,所以,组方不存在安全问题。
具体的配方组成为(按重量百分数):
海藻酸钾(低分子量海藻酸钾):20
红曲:10
燕麦β-葡聚糖:20
葛根提取物:10
大麦若叶粉:35
茶粉:4
木糖醇:1
生产加工方法如下:
步骤1. 粉碎过筛:将上述原辅料粉碎过筛,100%过80目,备用;
步骤2. 称重配料:按配方比例称取原辅料。;
步骤3. 混合搅拌:将配好后的粉料装入混合机内搅拌30min;
步骤4. 分装:将搅拌后的粉料用自动灌装机进行分装;
步骤5. 包装:将分装后的半成品包装入库。
本发明是通过实施例进行描述的,本领域技术人员知悉,在不脱离本发明的精神和范围的情况下,可以对这些特征和实施例进行各种改变或等效替换。另外,在本发明的教导下,可以对这些特征和实施例进行修改以适应具体的情况及材料而不会脱离本发明的精神和范围。因此,本发明不受此处所公开的具体实施例的限制,所有落入本申请的权利要求范围内的实施例都属于本发明的保护范围。
Claims (6)
1.一种辅助降血压降血糖的固体饮料,其特征在于:按照重量百分含量包括以下组分:海藻酸钾0.1-95%、山楂提取物0-95%、小麦低聚肽0-95%、辣木叶粉或辣木叶提取物0-95%、红曲米粉0-90%、纳豆粉0-90%、燕麦β-葡聚糖0-90%、壳寡糖0-50%、盐藻及提取物0-90%、竹叶黄酮0-90%、葛根或葛根提取物0-85%;菊粉0-90%、抗性糊精0-90%、豆粉0-95%、茶粉0-95%、奶粉0-95%、大麦若叶粉0-85%、柑橘纤维粉0-90%、咖啡粉0-95%;其中,辅料为菊粉、抗性糊精、豆粉、茶粉、奶粉、大麦若叶粉、柑橘纤维粉、咖啡粉,其余为功效成分;且辅料重量百分含量不同时为0。
2.根据权利要求1所述的一种辅助降血压降血糖的固体饮料,其特征在于:还包括矫味剂,矫味剂用量为功效成分和辅料总量的0.01~90%;矫味剂选自甜菊糖苷、木糖醇、低聚果糖、异麦芽糖醇、海藻糖、抹茶粉、果蔬粉、食用香精、柠檬酸、柠檬酸钠中的一种或几种。
3.上述辅助降血压降血糖的固体饮料的制备方法,其特征在于:包括以下步骤:
步骤1:粉碎过筛,将功效成分、辅料和矫味剂粉碎过筛,保证要进行加工的固体饮料的原料、辅料和矫味剂的粒度一致;
步骤2:称量,将功效成分、辅料和矫味剂进行精确称量,备用;
步骤3:混合搅拌,将称量好的功效成分、辅料、矫味剂按照配方进行混合搅拌混合均匀。
4.根据权利要求3所述的辅助降血糖的固体饮料的其制备方法,其特征在于:包括以下步骤4:制粒,将混合好的原料,根据需要进行制粒,粒度为20-60目。
5.根据权利要求3所述的辅助降血糖的固体饮料的其制备方法,其特征在于:所述步骤1中,功效成分、辅料和矫味剂粉碎过筛,100%过80目。
6.根据权利要求3所述的辅助降血糖的固体饮料的其制备方法,其特征在于:所述步骤3中,采用等量递增方法进行混合搅拌,保证功效成分、辅料、矫味剂混合均匀。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710016859.5A CN106819750A (zh) | 2017-01-11 | 2017-01-11 | 一种辅助降血压降血糖的固体饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710016859.5A CN106819750A (zh) | 2017-01-11 | 2017-01-11 | 一种辅助降血压降血糖的固体饮料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106819750A true CN106819750A (zh) | 2017-06-13 |
Family
ID=59117428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710016859.5A Pending CN106819750A (zh) | 2017-01-11 | 2017-01-11 | 一种辅助降血压降血糖的固体饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106819750A (zh) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107348299A (zh) * | 2017-07-31 | 2017-11-17 | 湖州金诺康健康科技有限公司 | 一种具有护肝解酒功效的固体饮料 |
CN107771946A (zh) * | 2017-10-28 | 2018-03-09 | 卜球 | 一种有助于中老年人心脑血管健康的配方奶粉及其生产方法 |
CN108157971A (zh) * | 2018-02-08 | 2018-06-15 | 沈勇子 | 一种壳寡糖液体口服制剂及其制备方法 |
CN108175016A (zh) * | 2018-01-03 | 2018-06-19 | 杭州衡美食品科技有限公司 | 一种生酮固体饮料及其制备方法 |
CN108272970A (zh) * | 2018-03-12 | 2018-07-13 | 厦门劳斯克食品有限公司 | 一种辅助降血脂的植物提取组合物及其制备方法和固体饮料 |
CN108514062A (zh) * | 2018-03-07 | 2018-09-11 | 佛山市真红生物制品有限公司 | 多糖红曲复方食疗代餐固体饮料及其制备方法 |
CN108576346A (zh) * | 2018-03-30 | 2018-09-28 | 李乃彬 | 一种能抗癌降压降糖降血脂的桦褐孔菌压片糖果 |
CN109010383A (zh) * | 2018-10-29 | 2018-12-18 | 南京轶萃康健康科技有限公司 | 一种有助改善肠动力的组合物及其制备方法 |
CN109315576A (zh) * | 2018-10-12 | 2019-02-12 | 肖文中 | 纳豆竹叶黄酮压片糖果 |
CN112655974A (zh) * | 2021-01-29 | 2021-04-16 | 安徽天凯生物科技有限公司 | 一种调节三高产品配方 |
CN112913933A (zh) * | 2021-03-22 | 2021-06-08 | 齐齐哈尔市碾子山乳品有限责任公司 | 一种降三高奶粉及其制备 |
CN113519631A (zh) * | 2021-07-06 | 2021-10-22 | 黑龙江谱华威乳业集团有限公司 | 一种辅助降血糖的低血糖负荷中老年调制乳粉及制备方法 |
CN113575694A (zh) * | 2021-07-15 | 2021-11-02 | 黑龙江谱华威乳业集团有限公司 | 一种含有辅助降血脂、降血压组合物的低脂肪调制乳粉 |
CN113730547A (zh) * | 2021-09-17 | 2021-12-03 | 江苏协合转化医学研究院有限公司 | 一种降脂、溶解血栓组合物及其制备方法和应用 |
CN114010773A (zh) * | 2021-10-26 | 2022-02-08 | 江苏协合转化医学研究院有限公司 | 一种降血压且无副作用的组合物配方及其制备工艺和用途 |
CN114081172A (zh) * | 2020-08-25 | 2022-02-25 | 上海屹泽生物科技有限公司 | 一种控血糖控血压组合物、控血糖控血压压片糖果及其制备方法 |
CN115399391A (zh) * | 2022-09-02 | 2022-11-29 | 盐城工学院 | 一种大麦若叶粉绿茶泡腾片及其制备方法 |
CN115426898A (zh) * | 2020-04-16 | 2022-12-02 | 三菱商事生命科学株式会社 | 包含被葡聚糖覆盖的组合物的食品物性改良剂 |
CN115960165A (zh) * | 2022-08-17 | 2023-04-14 | 华南农业大学 | 一种来源于辣木叶的富硒ace抑制肽及其应用 |
-
2017
- 2017-01-11 CN CN201710016859.5A patent/CN106819750A/zh active Pending
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107348299A (zh) * | 2017-07-31 | 2017-11-17 | 湖州金诺康健康科技有限公司 | 一种具有护肝解酒功效的固体饮料 |
CN107771946A (zh) * | 2017-10-28 | 2018-03-09 | 卜球 | 一种有助于中老年人心脑血管健康的配方奶粉及其生产方法 |
CN108175016A (zh) * | 2018-01-03 | 2018-06-19 | 杭州衡美食品科技有限公司 | 一种生酮固体饮料及其制备方法 |
CN108157971A (zh) * | 2018-02-08 | 2018-06-15 | 沈勇子 | 一种壳寡糖液体口服制剂及其制备方法 |
CN108514062A (zh) * | 2018-03-07 | 2018-09-11 | 佛山市真红生物制品有限公司 | 多糖红曲复方食疗代餐固体饮料及其制备方法 |
CN108272970A (zh) * | 2018-03-12 | 2018-07-13 | 厦门劳斯克食品有限公司 | 一种辅助降血脂的植物提取组合物及其制备方法和固体饮料 |
CN108576346A (zh) * | 2018-03-30 | 2018-09-28 | 李乃彬 | 一种能抗癌降压降糖降血脂的桦褐孔菌压片糖果 |
CN109315576A (zh) * | 2018-10-12 | 2019-02-12 | 肖文中 | 纳豆竹叶黄酮压片糖果 |
CN109010383A (zh) * | 2018-10-29 | 2018-12-18 | 南京轶萃康健康科技有限公司 | 一种有助改善肠动力的组合物及其制备方法 |
CN115426898A (zh) * | 2020-04-16 | 2022-12-02 | 三菱商事生命科学株式会社 | 包含被葡聚糖覆盖的组合物的食品物性改良剂 |
CN114081172A (zh) * | 2020-08-25 | 2022-02-25 | 上海屹泽生物科技有限公司 | 一种控血糖控血压组合物、控血糖控血压压片糖果及其制备方法 |
CN112655974A (zh) * | 2021-01-29 | 2021-04-16 | 安徽天凯生物科技有限公司 | 一种调节三高产品配方 |
CN112913933A (zh) * | 2021-03-22 | 2021-06-08 | 齐齐哈尔市碾子山乳品有限责任公司 | 一种降三高奶粉及其制备 |
CN113519631A (zh) * | 2021-07-06 | 2021-10-22 | 黑龙江谱华威乳业集团有限公司 | 一种辅助降血糖的低血糖负荷中老年调制乳粉及制备方法 |
CN113519631B (zh) * | 2021-07-06 | 2023-07-18 | 黑龙江谱华威乳业集团有限公司 | 一种辅助降血糖的低血糖负荷中老年调制乳粉及制备方法 |
CN113575694A (zh) * | 2021-07-15 | 2021-11-02 | 黑龙江谱华威乳业集团有限公司 | 一种含有辅助降血脂、降血压组合物的低脂肪调制乳粉 |
CN113730547A (zh) * | 2021-09-17 | 2021-12-03 | 江苏协合转化医学研究院有限公司 | 一种降脂、溶解血栓组合物及其制备方法和应用 |
CN114010773A (zh) * | 2021-10-26 | 2022-02-08 | 江苏协合转化医学研究院有限公司 | 一种降血压且无副作用的组合物配方及其制备工艺和用途 |
CN115960165A (zh) * | 2022-08-17 | 2023-04-14 | 华南农业大学 | 一种来源于辣木叶的富硒ace抑制肽及其应用 |
CN115960165B (zh) * | 2022-08-17 | 2024-06-11 | 华南农业大学 | 一种来源于辣木叶的富硒ace抑制肽及其应用 |
CN115399391A (zh) * | 2022-09-02 | 2022-11-29 | 盐城工学院 | 一种大麦若叶粉绿茶泡腾片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106819750A (zh) | 一种辅助降血压降血糖的固体饮料及其制备方法 | |
CN106983052A (zh) | 一种辅助降血糖的固体饮料及其制备方法 | |
CN104432084B (zh) | 一种调理粉及其制备方法和用途 | |
CN106666312A (zh) | 一种辅助降血糖的保健食品及其颗粒剂和胶囊剂制备方法 | |
CN103099089A (zh) | 一种降糖、降压、通便减肥、抗疲劳、改善性功能保健品及其生产工艺 | |
CN101057643B (zh) | 降糖大米 | |
CN105851165A (zh) | 一种保健广式五仁叉烧月饼及其制作方法 | |
CN110051815A (zh) | 一种辅助降血糖食丸及其制备方法 | |
CN106550970A (zh) | 一种苦荞蛋糕 | |
CN102204649A (zh) | 一种调节及稳定血糖的保健食品及制备方法 | |
CN105996028A (zh) | 生姜提取物、生姜纤维及其制备方法 | |
CN101703702A (zh) | 一种降脂减肥茶的制作方法 | |
CN103478560B (zh) | 一种用牛奶和绞股蓝制造的营养大米 | |
CN107613998A (zh) | 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品 | |
CN102511876B (zh) | 山楂红枣浓浆及其生产工艺 | |
CN107692241A (zh) | 一种具有减脂纤体功能的红薯膳食纤维及其制备方法 | |
CN107095139A (zh) | 有机燕麦营养粉的制作方法 | |
CN108095054B (zh) | 一种减少膳食中糖分消化和吸收的植物性胶囊及其制备方法 | |
CN114515005B (zh) | 一种含有菊花成分的薏苡仁提取物及其制备方法与应用 | |
CN108450941A (zh) | 一种调节脂代谢的膳食组合物 | |
CN107637736A (zh) | 一种魔芋甘露运动饮料及其制备方法 | |
CN106614968A (zh) | 铁皮石斛养生饼干及其制备方法 | |
CN109316565B (zh) | 一种降血脂组合物及其制备方法和应用 | |
CN106754057A (zh) | 一种保健红曲糯米酒及其制备方法 | |
CN106901082A (zh) | 沙棘甲壳素防三高饮料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170613 |